The Motley Fool

The Orthocell share price is going nuts on claims of a blockbuster medical breakthrough

The Orthocell Ltd (ASX: OCC) share price is up 25% to 50 cents today after the regenerative medicine researcher announced trial results showed its medical device CelGro® had helped quadriplegics regain arm and hand functions. 

CelGro® is reportedly used by surgeons to help patients regain muscle function via nerve regeneration treatment.

According to the company 12 patients undertook the trial with 86% of them subsequently reducing or ceasing to need prescription medication for chronic nerve pain 12 months after their treatment with CelGro®.

While 96% of “nerve repairs restored voluntary movement to previously paralysed muscle” in allowing previously quadriplegic patients to now undertake some common everyday tasks. 

Orthocell estimates CelGro®’s addressable market to be worth around US$1.1 billion annually, with 700,000 procedures completed each year that could be improved by CelGro®.

All this sounds exciting and at 50 cents per share Orthocell now has a market value around $74 million. For the 12 months to June 30 2019 it posted a net loss of $5.8 million on sales of $945,657. 

I would not suggest buying Orthocell shares myself, but the share price action shows it’s exciting risk on investors. 

Other speculative biotech picks exciting investors include Althea Group Holdings Ltd (ASX: ATH) Paradigm Biopharmaceuticals Ltd (ASX: PAR) and Opthea Ltd (ASX: OPT).

These 3 stocks could be the next big movers in 2020

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

*Returns as of 6/8/2020

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Related Articles...

Latest posts by Tom Richardson (see all)